AnnaPalmerDurbinMD

Infectious Disease • Baltimore, MD

Associate Professor

Join to view full profile

Dr. Durbin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Durbin's full profile

Already have an account?

Office
1800 Orleans Street
Baltimore, MD 21287
Phone+1 410-955-5000

Fax+1 410-955-5001

Education & Training

Detroit Medical Center/Wayne State UniversityFellowship, Infectious Disease, 1991 - 1994
Detroit Medical Center/Wayne State UniversityResidency, Internal Medicine, 1987 - 1991
Wayne State University School of MedicineClass of 1987

Certifications & Licensure

MD State Medical License 1994 - 2026
MI State Medical License 1983 - 2015
DC State Medical License 2006 - 2013
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Infectious Disease

Clinical Trials

Safety of and Immune Response to a Dengue Virus Vaccine (rDEN1delta30) in Healthy Adults Start of enrollment: 2004 Sep 01
Completed
Phase 1
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN2/4delta30[ME]) in Healthy Adults Start of enrollment: 2005 Jan 01
Completed
Phase 1
Safety of and Immune Response to a West Nile Virus Vaccine (WN/DEN4-3'delta30) in Healthy Adults Start of enrollment: 2005 Feb 01
Completed
Phase 1
Safety of and Immune Response to a Tick-Borne Encephalitis Vaccine (LGT(TP21)/DEN4) in Healthy Adults Start of enrollment: 2005 Jul 01
Completed
Phase 1
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-200,201) in Healthy Adults Start of enrollment: 2006 Jun 01
Completed
Phase 1
Safety of and Immune Response to a Malaria Vaccine (MSP1 42-C1) With or Without CPG 7909 Adjuvant Start of enrollment: 2006 Mar 01
Completed
Phase 1
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-4995) in Healthy Adults Start of enrollment: 2007 Jan 01
Completed
Phase 1
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3/4delta30[ME]) in Healthy Adults Start of enrollment: 2006 Oct 01
Completed
Phase 1
Safety of and Immune Response to Two Different Dengue Virus Vaccines in Individuals Previously Immunized Against Dengue Virus Start of enrollment: 2007 Mar 01
Completed
Phase 1
Safety of and Immune Response of a 2-dose Regimen of rDEN1delta30 Dengue Virus Vaccine Start of enrollment: 2007 May 01
Completed
Phase 1
Safety of and Immune Response to a West Nile Virus Vaccine (WN/DEN4delta30) in Healthy Adults Start of enrollment: 2008 Mar 01
Completed
Phase 1
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3-3'Ddelta30) in Healthy Adults Start of enrollment: 2008 Dec 01
Completed
Phase 1
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3delta30/31-7164) in Healthy Adults Start of enrollment: 2009 Sep 01
Completed
Phase 1
Safety of and Immune Response to DEN4 Vaccine Component Candidate for Dengue Virus Start of enrollment: 2009 Jul 01
Completed
Phase 1
Safety and Immune Response to Two Doses of rDEN2/4delta30 Dengue Vaccine Start of enrollment: 2009 Jan 01
Completed
Phase 1
Evaluation of the Safety and Immune Response of Five Admixtures of a Tetravalent Dengue Virus Vaccine Start of enrollment: 2010 Jul 01
Completed
Phase 1
Evaluation of the Safety and Immune Response to an Investigational Dengue Type 1 Vaccine Start of enrollment: 2010 Apr 01
Completed
Phase 1
Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine Start of enrollment: 2011 Aug 01
Completed
Phase 1
Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine Start of enrollment: 2011 Dec 01
Completed
Phase 1
Evaluating the Safety and Immune Response to Two Doses of a Dengue Virus Vaccine Administered 12 Months Apart Start of enrollment: 2013 Jan 01
Completed
Phase 1
Evaluating the Safety and Immune Response to a Dengue Virus Vaccine in Healthy Adults Start of enrollment: 2013 Jun 01
Completed
Phase 1
Evaluating the Safety and Effectiveness of a Dengue Virus Vaccine in Healthy Adults Start of enrollment: 2013 Nov 01
Completed
Phase 1
Evaluating the Safety and Immunogenicity of a Live Attenuated West Nile Virus Vaccine for West Nile Encephalitis in Adults 50 to 65 Years of Age Start of enrollment: 2014 Feb 01
Completed
Phase 1
Evaluation of the Efficacy of the Live Attenuated Tetravalent Dengue Vaccine Against DENV-2 and DENV-3 Challenge Start of enrollment: 2017 Nov 28
Completed
Phase 1
Evaluation of Two Zika Viruses for Use in Controlled Human Infection Models (CHIM) Start of enrollment: 2022 Feb 16
Recruiting
Phase 1
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Localized Inflammation in Dengue Vaccine-Induced Skin Rash Is Not Associated with Continuous Presence of Dengue Virus Genome.
Camilla Strother, Nicole Bouffard, Olha Smolynets, Nancy R Graham, Evan A Elko
The Journal of Investigative Dermatology. 2024-12-27
1 citations
Precision arbovirus serology with a pan-arbovirus peptidome.
William R Morgenlander, Wan Ni Chia, Beatriz Parra, Daniel R Monaco, Izabela Ragan
Nature Communications. 2024-07-11
2 citations
Fourth Controlled Human Infection Model (CHIM) meeting - CHIMs in endemic countries, May 22-23, 2023.
Melissa Kapulu, Lucinda Manda-Taylor, Shobana Balasingam, Gary Means, Mikal Ayiro Malungu
Biologicals. 2024-02-01

Press Mentions

COVID Gave Rise to Vaccine Skepticism. That May Affect Preparedness for Next PandemicMarch 22nd, 2025
Do the Covid Vaccines Provide Long-Lasting Protection?November 3rd, 2024
Another AIDS Vaccine Day, yet No Vaccine for AIDSMay 19th, 2023
Join now to see all

Grant Support

Mechanisms of Protection and Durability for a Live Attenuated Tetravalent Dengue VaccineUNIVERSITY OF VERMONT & ST AGRIC COLLEGE2019–2029
Mechanisms of Protection and Durability for a Live Attenuated Tetravalent Dengue VaccineUNIVERSITY OF VERMONT & ST AGRIC COLLEGE2019–2029
A STUDY TO ASSESS EFFICACY, SAFTETY AND PHARMACOKINETICS OF EYU688 IN HEALTHY PARTICIPANTS CHALLENGED WITH DENGUE SEROTYPE 2JOHNS HOPKINS UNIVERSITY2023–2025
A STUDY TO ASSESS EFFICACY, SAFTETY AND PHARMACOKINETICS OF EYU688 IN HEALTHY PARTICIPANTS CHALLENGED WITH DENGUE SEROTYPE 2JOHNS HOPKINS UNIVERSITY2023–2025